Atlas Trials

Ascletis Pharma (China) Co., Limited

9 clinical trials · Sponsor

Sort:Newest firstOldest first

◉ Watch Ascletis Pharma (China) Co., Limited

RecordFirmDate
A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes (NCT07743450)Ascletis Pharma (China) Co., Limited2026-08-01
A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities (NCT07743463)Ascletis Pharma (China) Co., Limited2026-08-01
A Study to Evaluate the Efficacy, Safety, and Tolerability of ASC30 Tablets in Participants With Type 2 Diabetes Mellitus (NCT07321678)Ascletis Pharma (China) Co., Limited2026-01-22
A Study to Evaluate the Efficacy, Safety, and Tolerability in Participants With Obesity or Overweight With Weight-Related Comorbidities (NCT07002905)Ascletis Pharma (China) Co., Limited2025-07-03
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of ASC50 Tables in Healthy Participants and Participants With Plaque Psoriasis (NCT07024602)Ascletis Pharma (China) Co., Limited2025-06-01
A Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASC47 in Combination With Semaglutide (NCT06972992)Ascletis Pharma (China) Co., Limited2025-04-18
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of ASC30 Injection in Participants With Obesity (NCT06679959)Ascletis Pharma (China) Co., Limited2024-09-16
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of ASC30 Tablets and ASC30 Tablets A1 in Participants With Obesity (NCT06680440)Ascletis Pharma (China) Co., Limited2024-08-26
A Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASC47 in Healthy and Obese Subjects (NCT06427590)Ascletis Pharma (China) Co., Limited2024-07-13

Track Ascletis Pharma (China) Co., Limited automatically

Every clearance here is in the API, with alerts when new ones post.